Industry News


D.R. Horton, Shell, FCX, senior loans among picks at Barron's Roundtable

6h seekingalpha
Delphi Management's Scott Black reloads his D.R. Horton (NYSE:DHI) idea from the Midyear Roundtable, noting it's a rare homebuilder with positive free cash flow and low debt. Affordability, however, is an issue - the company says 22-23% of would-be customers looking for financing don't qualify.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Derma Sciences, Inc. - DSCI

2017-01-21 accesswire
BALA CYNWYD, PA / ACCESSWIRE / January 20, 2017 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Derma Sciences, Inc. ("Derma Sciences" or "the Company") (NASDAQ: DSCI - News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to LifeSciences Holding Corporation.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid Pharmaceuticals, Inc. -CLCD

2017-01-20 prnewswire
BALA CYNWYD, Pa., Jan. 20, 2017 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of CoLucid Pharmaceuticals, Inc. ("CoLucid" or "the Company") (NASDAQ: CLCD) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Eli Lilly and Company ("Eli Lilly").

Falling Earnings Estimates Signal Weakness Ahead for MiMedx Group (MDXG)

2017-01-20 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. One such stock that you may want to consider dropping is MiMedx Group, Inc. (MDXG - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.

Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA

2017-01-20 zacks
Shire plc (SHPG - Free Report) announced that the FDA has acknowledged receipt of the Class 2 resubmission of a New Drug Application (NDA) for pipeline candidate, SHP465. Shire’s shares have performed better the Zacks classified Medical-Drugs industry in the last twelve months. The stock lost 7.4% in the last twelve months which compared favorably to the industry’s 10.8% decline.

A First Look At CCL Industries

2017-01-20 seekingalpha
The share price went sideways for most of 2016, but experienced a significant jump upon their most recent acquisition announcement.

10 Value Stocks In This Uncertain Trump Market

2017-01-20 seekingalpha
Prior to President-elect Donald Trump's inauguration Friday, the Dow has lost value five trading days in a row. Many analysts attribute the recent pull back to the fact that there is still so much uncertainty surrounding a Trump administration. But isn't this the same uncertainty that helped US equities rally to record highs after Trump's victory back in November?

4 Reasons To Avoid GE And Buy This Far Superior Industrial Dividend Growth Legend

2017-01-20 seekingalpha
GE Capital's disasterous performance during the financial crisis cost GE investors dearly, especially those who owned the stock for its venerable dividend aristocrat status.

RMS Medical Announces Hiring of Eric Bauer as Chief Operating Officer

2017-01-20 accesswire
CHESTER, NY / ACCESSWIRE / January 20, 2017 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) ("RMS" or the "Company") announced today that Mr. Eric Bauer has joined the executive team as Chief Operating Officer, effective January 17, 2017. Mr. Bauer brings to RMS over 25 years of experience driving operational excellence in growing organizations within FDA regulated environments.

Global MEMS Microphone Market Analysis & Trends 2013-2025: Market to Grow at a CAGR of 12.1% to Reach Approximately $3.58 Billion - Research and Markets

2017-01-20 prnewswire
Research and Markets has announced the addition of the "MEMS Microphone Market Analysis & Trends - Application (Hearing aid, Consumer electronics, Automotive and Mobile phones) - Forecast to 2025" report to their offering.

Research and Markets - Global Left Atrial Appendage Closure Market Growth at CAGR of 33.54% by 2021, with AtriCure, Boston Scientific, Coherex Medical & St. Jude Medical Dominating

2017-01-20 prnewswire
Research and Markets has announced the addition of the "Global Left Atrial Appendage Closure Market 2017-2021" report to their offering.

Research and Markets - Global Virtual Events Market Growth at a CAGR of 21.97%, 2017-2021 with Adobe Systems, Avaya, Cisco Systems, Citrix Systems, IBM & Microsoft Dominating

2017-01-20 prnewswire
Research and Markets has announced the addition of the "Global Virtual Events Market 2017-2021" report to their offering.

Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy

2017-01-20 zacks
Shares of Bristol-Myers Squibb Company (BMY - Free Report) fell 5% in afterhours trading on Jan 19 after the company disclosed that it will not seek an accelerated approval in the U.S. for a combination of its two immuno-oncology treatments, Opdivo plus Yervoy, for first-line lung cancer. The company said the decision was based on a review of data that are available at this time.

The MnM Portfolio, December 2016: Ep. 22 - Closing Out A Strong 2016

2017-01-20 seekingalpha
This month's article marks the twenty-second installment in my on-going series outlining my efforts to achieve dividend growth success. The portfolio is nicknamed the MnM portfolio, which is a moniker for "Minne(sota) 'n Monthly."

Medical Product Stocks Q4 Earnings Roster: SYK, ISRG, RMD

2017-01-20 zacks
The fourth-quarter earnings season is in its nascent stage with 41 S&P 500 participants having reported results so far. According to our latest Earnings Trends report, the earnings cycle has seen an encouraging start, courtesy of stable bank results. The uptrend was the result of reduced regulatory burden, tax law changes and an improved outlook for the domestic economy. Per the latest Earnings Trends report, the fourth-quarter earnings for the S&P 500 companies are expected to be up 4.

Aduro (ADRO) Inks License Agreement with Stanford University

2017-01-20 zacks
Aduro Biotech, Inc. (ADRO - Free Report) announced that it has inked an exclusive license agreement with Stanford University for state-of-the-art neo-antigen identification technology. The company will leverage its proprietary live, attenuated double-deleted Listeria (LADD) immunotherapy platform to cater to personalized LADD-based cancer therapies (pLADD) and help encode a number of neoantigens identified through this technology.

Quest Diagnostics (DGX) Launches HBV Quantitative Test

2017-01-20 zacks
Quest Diagnostics Inc. (DGX - Free Report) , a global provider of diagnostic information services, recently rolled out Hepatitis B Virus (HBV) Quantitative Test. This helps physicians evaluate a patient's response to drug therapies for HBV infection. The test is first of its kind in the U.S. and will help effectively treat individuals infected with the virus.

San Diego's Cytori Scoops Up Azaya Therapeutics in Deal Worth $170 Million

2017-01-20 biospace
Proposed Acquisition of Azaya Therapeutics Assets Would Broaden Pipeline with Two Oncology Drugs for Large, Underserved Markets

Have Faith In Trump's Agenda - Cramer's Mad Money (1/19/17)

2017-01-20 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, January 19.

Novocure's Optune available at 500 U.S. cancer centers; shares ahead 10% premarket

2017-01-20 seekingalpha
Novocure (NASDAQ:NVCR) announces that doctors at 500 U.S. cancer centers have been certified to prescribe Optune to treat newly diagnosed and recurrent glioblastoma patients.

IRADIMED CORPORATION announces FY2017 and Q1 guidance; shares off 19%

2017-01-20 seekingalpha
For 2017, Company expects revenue of $23.9M -$24.3M, GAAP EPS of $0.07 - $0.08 and non-GAAP EPS of $0.14 - $0.18.

Amedica prices equity offering; shares down 32%

2017-01-20 seekingalpha
Penny stock Amedica (AMDA -32%) slumps on more than a 4x surge in volume in response to the pricing of its $4.5M public equity offering. The company is offering one share of common stock paired with 0.45 of a warrant to purchase one common share at $0.55 for a combined price of $0.51. Closing date is January 24.

Mallinckrodt to Pay $100M Fine to FTC for Questcor Matter

2017-01-20 zacks
Mallinckrodt plc (MNK - Free Report) , will have to pay a fine of $100 million to the U.S. Federal Trade Commission (FTC) to resolve the latter’s investigation into the acquisition of Synacthen Depot by its Questcor division. Synacthen Depot, is a synthetic adrenocorticotropic hormone (ACTH) drug.

IBM And 3M Face Off In The Final Conference Championship Match

2017-01-19 seekingalpha
Who will win this battle of Dow titans that have been in the index since the 1970s?

Implantable Biomaterials Market Material, Application Analysis & Trends 2016-2025: $150+ Billion Growth Opportunities/Investment Opportunities - Research and Markets

2017-01-19 prnewswire
The Global Implantable Biomaterials Market is poised to grow at a CAGR of around 7.5% over the next decade to reach approximately $165.31 billion by 2025.